{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:03:02Z","timestamp":1785171782575,"version":"3.55.0"},"posted":{"date-parts":[[2026,4,10]]},"group-title":"In Review","reference-count":42,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,28]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n Tuberculosis (TB) treatment outcomes in sub-Saharan Africa remain suboptimal despite high adherence to first-line therapy. Variability in drug pharmacokinetics, resulting in subtherapeutic plasma concentrations, may contribute to treatment failure and the development of resistance. This study estimated the causal effect of subtherapeutic plasma concentrations of first-line anti-TB drugs on treatment failure or death among individuals with drug-susceptible pulmonary TB in Ghana.\nMethods\n We conducted a prospective cohort study of 164 adults receiving standard WHO weight-band dosing at five Ghanaian hospitals. Peak plasma concentrations (C\n                  <sub>max<\/sub>\n                  ) of rifampicin, isoniazid, pyrazinamide, and ethambutol were measured at months 1\u20132 using validated LC-MS\/MS. We emulated a target trial comparing two static strategies: (1) therapeutic C\n                  <sub>max<\/sub>\n                  of at least one first-line drug versus (2) subtherapeutic C\n                  <sub>max<\/sub>\n                  of all four drugs. Using the clone-censor-weight approach, we estimated the per-protocol analogue risk difference (RD) and risk ratio (RR) for treatment failure (smear positive at months 5 or 6) or death by month 6. Models were adjusted for baseline covariates using inverse probability of censoring weighting. Sensitivity analyses included inverse probability weighting with regression adjustment, plain inverse probability weighting, and E-values.\nResults\n Of 164 participants, 120 had complete pharmacokinetic and outcome data; 20.0% (24\/120) had subtherapeutic concentrations of all four drugs. The 6-month risk of treatment failure or death was 33.3% under the low-exposure strategy versus 4.2% under the adequate-exposure strategy (crude RD: 29.1 percentage points). In weighted analyses, low drug exposure was associated with a 25.6 percentage-point increase in absolute risk of treatment failure or death (95% CI: 5.7\u201345.6; p\u2009=\u20090.012) and an 8.6-fold higher relative risk (95% CI: 2.34\u201331.92; p\u2009=\u20090.001), corresponding to approximately one additional poor outcome for every four patients with subtherapeutic levels. Sensitivity analyses were consistent (ATE: 19.9%, 95% CI: 2.3\u201337.5). The E-value was 15.5 (lower bound 5.0).\nConclusions\n Subtherapeutic exposure to all four first-line drugs was strongly associated with increased risk of treatment failure or death. Preventing multidrug subtherapeutic exposure through therapeutic drug monitoring or optimized dosing warrants randomized evaluation in high-burden settings.\nTrial registration\n Clinical trial number: not applicable.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9255541\/v1","type":"posted-content","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:34:15Z","timestamp":1775802855000},"source":"Crossref","is-referenced-by-count":0,"title":["Exposure to the Four First-Line Anti-Tuberculosis Drugs and Treatment Outcomes: A Target Trial Emulation Study in Ghana"],"prefix":"10.21203","author":[{"given":"Michael","family":"Opoku-Mireku","sequence":"first","affiliation":[{"name":"University of Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Y. M.","family":"Lartey","sequence":"additional","affiliation":[{"name":"Korle Bu Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[{"name":"University of Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divine Yao Aseye","family":"Amenuke","sequence":"additional","affiliation":[{"name":"Komfo Anokye Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwasi Adjepong","family":"Twum","sequence":"additional","affiliation":[{"name":"Komfo Anokye Teaching Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla A.","family":"Nortey","sequence":"additional","affiliation":[{"name":"University of Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Ansah","family":"Manu","sequence":"additional","affiliation":[{"name":"University of Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwadwo Ansah","family":"Koram","sequence":"additional","affiliation":[{"name":"University of Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO. Global Tuberculosis Report 2024 [Internet]. 2024 [cited 2025 Jan 23]. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024"},{"key":"ref2","unstructured":"World Bank Group. World Bank Open Data [Internet]. 2025 [cited 2025 Mar 10]. World Bank Open Data. Available from: https:\/\/data.worldbank.org"},{"issue":"6","key":"ref3","doi-asserted-by":"publisher","first-page":"e0252819","DOI":"10.1371\/journal.pone.0252819","article-title":"The burden of drug resistance tuberculosis in Ghana; results of the First National Survey","volume":"16","author":"Sylverken AA","year":"2021","unstructured":"Sylverken AA, Kwarteng A, Twumasi-Ankrah S, Owusu M, Arthur RA, Dumevi RM, et al. The burden of drug resistance tuberculosis in Ghana; results of the First National Survey. PLoS ONE. 2021;16(6):e0252819. 10.1371\/journal.pone.0252819. PubMed PMID: 34111159; PubMed Central PMCID: PMC8191906.","journal-title":"PLoS ONE"},{"issue":"2","key":"ref4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy","volume":"55","author":"Pasipanodya JG","year":"2012","unstructured":"Pasipanodya JG, Srivastava S, Gumbo T. Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy. Clin Infect Dis. 2012;55(2):169\u201377. 10.1093\/cid\/cis353.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/infdis\/jir658","article-title":"Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability","volume":"204","author":"Srivastava S","year":"2011","unstructured":"Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability. J Infect Dis. 2011;204(12):1951\u20139. 10.1093\/infdis\/jir658.","journal-title":"J Infect Dis"},{"issue":"6","key":"ref6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.5588\/ijtld.15.0803","article-title":"Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis","volume":"20","author":"Mota L","year":"2016","unstructured":"Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(6):819\u201326. 10.5588\/ijtld.15.0803.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5588\/ijtld.19.0025","article-title":"A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes","volume":"24","author":"Perumal R","year":"2020","unstructured":"Perumal R, Naidoo K, Naidoo A, Ramachandran G, Requena-Mendez A, Sekaggya-Wiltshire C, et al. A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes. Int J Tuberc Lung Dis. 2020;24(1):48\u201364.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"ref8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.7196\/SAMJ.2023.v113i3.16761","article-title":"Clinical impact of plasma concentrations of first-line antituberculosis drugs","volume":"113","author":"Perumal R","year":"2023","unstructured":"Perumal R, Naidoo K, Naidoo A, Padayatchi N. Clinical impact of plasma concentrations of first-line antituberculosis drugs. S Afr Med J. 2023;113(3):148\u201353. 10.7196\/SAMJ.2023.v113i3.16761.","journal-title":"S Afr Med J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01701-16","author":"Antwi S","year":"2016","unstructured":"Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D et al. Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection. Antimicrob Agents Chemother. 2016;AAC.01701-16. 10.1128\/AAC.01701-16"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/jpids\/piv035","article-title":"Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection","volume":"5","author":"Kwara A","year":"2016","unstructured":"Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, et al. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. J Pediatr Infect Dis Soc. 2016;5(4):356\u201365. 10.1093\/jpids\/piv035.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"2","key":"ref11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jac\/dkr445","article-title":"Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso","volume":"67","author":"Saleri N","year":"2012","unstructured":"Saleri N, Demb\u00e9l\u00e9 SM, Villani P, Carvalho ACC, Cusato M, Bonkoungou V, et al. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. J Antimicrob Chemother. 2012;67(2):469\u201372. 10.1093\/jac\/dkr445. PubMed PMID: 22028201.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"ref12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5588\/ijtld.15","article-title":"Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand","volume":"20","author":"Maze MJ","year":"2016","unstructured":"Maze MJ, Paynter J, Chiu W, Hu R, Nisbet M, Lewis C. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2016;20(7):955\u201360. 10.5588\/ijtld.15. .0792 PubMed PMID: 27287650.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"5152","key":"ref13","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.4414\/smw.2015.14223","article-title":"Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges","volume":"145","author":"Meloni M","year":"2015","unstructured":"Meloni M, Corti N, M\u00fcller D, Henning L, Gutteck U, von Braun A, et al. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges. Swiss Med Wkly. 2015;145(5152):5152. 10.4414\/smw.2015.14223.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.00693-15","article-title":"Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome","volume":"60","author":"Park JS","year":"2015","unstructured":"Park JS, Lee JY, Lee YJ, Kim SJ, Cho YJ, Yoon HI, et al. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015;60(1):92\u20138. 10.1128\/AAC.00693-15. PubMed PMID: 26459901; PubMed Central PMCID: PMC4704228.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.180","article-title":"Optimizing the clinical pharmacology of tuberculosis medications","volume":"9","author":"Egelund EF","year":"2015","unstructured":"Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clin Pharmacol Ther. 2015;9(4). https:\/\/doi.org\/10.1002\/cpt.180.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"e1002202","DOI":"10.1371\/journal.pmed.1002202","article-title":"Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model","volume":"14","author":"Kendall EA","year":"2017","unstructured":"Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, et al. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Med. 2017;14(1):e1002202. 10.1371\/journal.pmed.1002202.","journal-title":"PLOS Med"},{"issue":"15","key":"ref17","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic Drug Monitoring in the Treatment of Tuberculosis","volume":"62","author":"Peloquin CA","year":"2002","unstructured":"Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs. 2002;62(15):2169\u201383. 10.2165\/00003495-200262150-00001.","journal-title":"Drugs"},{"issue":"12","key":"ref18","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana","volume":"48","author":"Chideya S","year":"2009","unstructured":"Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685\u201394. 10.1086\/599040.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"ref19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","article-title":"Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana","volume":"41","author":"Tappero JW","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum Concentrations of Antimycobacterial Drugs in Patients with Pulmonary Tuberculosis in Botswana. Clin Infect Dis. 2005;41(4):461\u20139. 10.1086\/431984.","journal-title":"Clin Infect Dis"},{"key":"ref20","volume-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014 and January 2020)","author":"WHO","year":"2013","unstructured":"WHO. Definitions and reporting framework for tuberculosis \u2013 2013 revision (updated December 2014 and January 2020). Report No; 2013."},{"issue":"9","key":"ref21","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya JG","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373. 10.1093\/infdis\/jit352. PubMed PMID: 23901086; PubMed Central PMCID: PMC3789573.","journal-title":"J Infect Dis"},{"key":"ref22","first-page":"1","volume-title":"Community involvement in tuberculosis care and prevention: towards partnerships for health: guiding principles and recommendations based on a WHO review","author":"World Health Organization, editor","year":"2008","unstructured":"World Health Organization, editor. Community involvement in tuberculosis care and prevention: towards partnerships for health: guiding principles and recommendations based on a WHO review. Geneva, Switzerland: World Health Organization; 2008. p. 1."},{"key":"ref23","author":"Standard Treatment","year":"2017","unstructured":"Ministry of Health, Ghana, Standard Treatment, Guidelines. 2017. 7th ed. Ghana National Drugs Programme; 2017."},{"key":"ref24","author":"Lixoft SAS","year":"2023","unstructured":"Lixoft SAS. a Simulations Plus company. Monolix 2023R1. 2023."},{"issue":"1","key":"ref25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17512433.2017.1246179","article-title":"The challenges of pharmacokinetic variability of first-line anti-TB drugs","volume":"10","author":"Devaleenal Daniel B","year":"2017","unstructured":"Devaleenal Daniel B, Ramachandran G, Swaminathan S. The challenges of pharmacokinetic variability of first-line anti-TB drugs. Expert Rev Clin Pharmacol. 2017;10(1):47\u201358. 10.1080\/17512433.2017.1246179. PubMed PMID: 27724114.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/23744235.2024.2309348","article-title":"Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis","volume":"56","author":"Sileshi T","year":"2024","unstructured":"Sileshi T, Makonnen E, Telele NF, Barclay V, Zumla A, Aklillu E. Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis. Infect Dis Lond Engl. 2024;56(4):308\u201319. PubMed PMID: 38315168; PubMed Central PMCID: PMC11134291.","journal-title":"Infect Dis Lond Engl"},{"issue":"4","key":"ref27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"VanderWeele TJ","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268\u201374. 10.7326\/M16-2607. PubMed PMID: 28693043.","journal-title":"Ann Intern Med"},{"key":"ref28","author":"Bang H","year":"2005","unstructured":"Bang H, Robins JM. Biometrics. 2005;61(4):962\u201373. 10.1111\/j.1541-0420.2005.00377.x. Doubly Robust Estimation in Missing Data and Causal Inference Models."},{"issue":"6","key":"ref29","doi-asserted-by":"publisher","first-page":"ofad255","DOI":"10.1093\/ofid\/ofad255","article-title":"Diabetes Mellitus and Tuberculosis Treatment Outcomes: Interaction Assessment Between Hyperglycemia and Human Immunodeficiency Virus in the State of Georgia, 2015\u20132020","volume":"10","author":"Houck K","year":"2023","unstructured":"Houck K, Chakhaia T, Gorvetzian S, Critchley JA, Schechter MC, Magee MJ. Diabetes Mellitus and Tuberculosis Treatment Outcomes: Interaction Assessment Between Hyperglycemia and Human Immunodeficiency Virus in the State of Georgia, 2015\u20132020. Open Forum Infect Dis. 2023;10(6):ofad255. 10.1093\/ofid\/ofad255.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"ref30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.5588\/ijtld.18.0433","article-title":"The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis","volume":"23","author":"Huangfu P","year":"2019","unstructured":"Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2019;23(7):783\u201396. 10.5588\/ijtld.18.0433. PubMed PMID: 31439109.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"7","key":"ref31","doi-asserted-by":"publisher","first-page":"e087218","DOI":"10.1136\/bmjopen-2024-087218","article-title":"Impact of HIV coinfection on tuberculosis treatment outcomes in Ethiopia: a systematic review and meta-analysis","volume":"14","author":"Mekonen H","year":"2024","unstructured":"Mekonen H, Negesse A, Dessie G, Desta M, Mihiret GT, Tarik YD, et al. Impact of HIV coinfection on tuberculosis treatment outcomes in Ethiopia: a systematic review and meta-analysis. BMJ Open. 2024;14(7):e087218. 10.1136\/bmjopen-2024-087218. PubMed PMID: 38969385; PubMed Central PMCID: PMC11228389.","journal-title":"BMJ Open"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.jinf.2024.106175","article-title":"Undernutrition increases the risk of unsuccessful treatment outcomes of patients with tuberculosis in Ethiopia: A multicenter retrospective cohort study","volume":"89","author":"Wagnew F","year":"2024","unstructured":"Wagnew F, Alene KA, Kelly M, Gray D. Undernutrition increases the risk of unsuccessful treatment outcomes of patients with tuberculosis in Ethiopia: A multicenter retrospective cohort study. J Infect. 2024;89(1):106175. 10.1016\/j.jinf.2024.106175. PubMed PMID: 38729526.","journal-title":"J Infect"},{"issue":"2","key":"ref33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/jac\/dkx380","article-title":"A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations","volume":"73","author":"Clewe O","year":"2018","unstructured":"Clewe O, Wicha SG, De Vogel CP, De Steenwinkel JEM, Simonsson USH. A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations. J Antimicrob Chemother. 2018;73(2):437\u201347. 10.1093\/jac\/dkx380.","journal-title":"J Antimicrob Chemother"},{"issue":"43","key":"ref34","doi-asserted-by":"publisher","first-page":"16741","DOI":"10.1074\/jbc.RA118.002693","article-title":"Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis","volume":"293","author":"Zhu C","year":"2018","unstructured":"Zhu C, Liu Y, Hu L, Yang M, He ZG. Molecular mechanism of the synergistic activity of ethambutol and isoniazid against Mycobacterium tuberculosis. J Biol Chem. 2018;293(43):16741\u201350. 10.1074\/jbc.RA118.002693.","journal-title":"J Biol Chem"},{"issue":"5","key":"ref35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/cid\/ciy","article-title":"Delayed Sputum Culture Conversion in Tuberculosis\u2013Human Immunodeficiency Virus\u2013Coinfected Patients With Low Isoniazid and Rifampicin Concentrations","volume":"67","author":"Sekaggya-Wiltshire C","year":"2018","unstructured":"Sekaggya-Wiltshire C, von Braun A, Lamorde M, Ledergerber B, Buzibye A, Henning L, et al. Delayed Sputum Culture Conversion in Tuberculosis\u2013Human Immunodeficiency Virus\u2013Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(5):708\u201316. 10.1093\/cid\/ciy. 179 PubMed PMID: 29514175; PubMed Central PMCID: PMC6094003.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"8","key":"ref36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/dmd.121","article-title":"Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug","volume":"49","author":"Hussain Z","year":"2021","unstructured":"Hussain Z, Zhu J, Ma X. Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug. Drug Metab Dispos. 2021;49(8):679\u201382. 10.1124\/dmd.121. .000389 PubMed PMID: 34074731; PubMed Central PMCID: PMC8407665.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"ref37","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cpt.3557","article-title":"Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases","volume":"117","author":"Malinga TVB","year":"2025","unstructured":"Malinga TVB, Othman H, Paximadis M, Tiemessen CT, Ramsay M, Hazelhurst S, et al. Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub-Saharan African Populations: Implications for Treatment of Tuberculosis and Other Diseases. Clin Pharmacol Ther. 2025;117(5):1338\u201357. 10.1002\/cpt.3557. PubMed PMID: 39829327; PubMed Central PMCID: PMC11993289.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"ref38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial MZ","year":"2018","unstructured":"Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):11. 10.1038\/s41591-018-0224-2.","journal-title":"Nat Med"},{"issue":"4","key":"ref39","doi-asserted-by":"publisher","first-page":"e1002773","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom N","year":"2019","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M, et al. Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization. PLOS Med. 2019;16(4):e1002773. 10.1371\/journal.pmed.1002773.","journal-title":"PLOS Med"},{"issue":"4","key":"ref40","doi-asserted-by":"publisher","DOI":"10.7754\/Clin","article-title":"Comparative Routine Therapeutic Drug Monitoring of Mycophenolic Acid in human Plasma with HPLC-UV and Isotope Dilution LC-MS\/MS","volume":"66","author":"Paal M","year":"2020","unstructured":"Paal M, Habler K, Northoff B, Vogeser M. Comparative Routine Therapeutic Drug Monitoring of Mycophenolic Acid in human Plasma with HPLC-UV and Isotope Dilution LC-MS\/MS. Clin Lab. 2020;66(4). 10.7754\/Clin. .Lab.2019.190820 PubMed PMID: 32255280.","journal-title":"Clin Lab"},{"issue":"2","key":"ref41","doi-asserted-by":"publisher","first-page":"e9425","DOI":"10.1002\/rcm.9425","article-title":"A high-throughput LC\u2013MS\/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma","volume":"37","author":"Pr\u0161o K","year":"2023","unstructured":"Pr\u0161o K, \u017didekov\u00e1 N, Porvazn\u00edk I, Solovi\u010d I, Mokr\u00fd J, Kertys M. A high-throughput LC\u2013MS\/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma. Rapid Commun Mass Spectrom. 2023;37(2):e9425. 10.1002\/rcm.9425. PubMed PMID: 36329637; PubMed Central PMCID: PMC9787364.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"ref42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot\u2013Based Methods for Therapeutic Drug Monitoring","volume":"41","author":"Capiau S","year":"2019","unstructured":"Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot\u2013Based Methods for Therapeutic Drug Monitoring. Ther Drug Monit. 2019;41(4):409. 10.1097\/FTD.0000000000000643.","journal-title":"Ther Drug Monit"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9255541\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9255541\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:14:32Z","timestamp":1785168872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9255541\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":42,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9255541\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12879-026-14061-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,4,10]]},"subtype":"preprint"}}